12.22

5.25% 0.61

After Hours: 12.50 0.28 +2.29%

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $12.22, with a volume of 1.05M. It is up +5.25% in the last 24 hours and down -19.02% over the past month. Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Previous Close:

$11.61

Open:

$11.76

24h Volume:

1.05M

Relative Volume:

1.00

Market Cap:

$555.64M

Revenue:

$27.10M

Net Income/Loss:

$-24.31M

P/E Ratio:

-14.72

EPS:

-0.83

Net Cash Flow:

$-33.33M

1W Performance:

-6.50%

1M Performance:

-19.02%

6M Performance:

+144.89%

1Y Performance:

+79.97%

1-Day Range:

$11.60

$12.38

1-Week Range:

$11.55

$13.92

52-Week Range:

$3.52

$23.40

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1171)

Industry

Biotechnology (670)

Phone

(310) 358-3200

Address

8840 WILSHIRE BLVD, BEVERLY HILLS, CA

Employee

102

Twitter

@Capricor

Next Earnings Date

2025-03-19

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	12.22	555.64M	27.10M	-24.31M	-33.33M	-0.83
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

05:46 AM

Earnings call transcript: Capricor Q4 2024 beats EPS forecast, stock up - Investing.com India

05:46 AM

05:15 AM

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

05:15 AM

05:02 AM

Capricor Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

05:02 AM

04:49 AM

Capricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of - GuruFocus.com

04:49 AM

04:43 AM

Capricor Therapeutics Q4 Loss Widens, Revenue Decreases -March 19, 2025 at 04:39 pm EDT - Marketscreener.com

04:43 AM

04:36 AM

Capricor: Q4 Earnings Snapshot - Danbury News Times

04:36 AM

04:18 AM

Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com - Investing.com UK

04:18 AM

04:15 AM

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView

04:15 AM

04:05 AM

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance

04:05 AM

07:15 AM

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St

07:15 AM

06:42 AM

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership - Yahoo Finance

06:42 AM

Mar 18, 2025

Capricor Therapeutics announces long-term data from HOPE-2 OLE study - Yahoo Finance

Mar 18, 2025

H.C. Wainwright maintains Capricor stock Buy rating and $77 target By Investing.com - Investing.com UK

Mar 18, 2025

Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025

Mar 17, 2025

CAPRICOR THERAPEUTICS Earnings Preview: Recent $CAPR Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 17, 2025

Capricor Therapeutics Announces Positive Data Demonstrating - GlobeNewswire

Mar 17, 2025

Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy - Marketscreener.com

Mar 17, 2025

Capricor reports promising DMD treatment results By Investing.com - Investing.com Australia

Mar 17, 2025

Breakthrough: New DMD Drug Cuts Disease Progression in Half Over 3 Years - StockTitan

Mar 17, 2025

Mar 16, 2025

When the Price of (CAPR) Talks, People Listen - Stock Traders Daily

Mar 16, 2025

Mar 14, 2025

Capricor touts long-term efficacy of DMD therapy ahead of FDA application - MSN

Mar 14, 2025

Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World

Mar 14, 2025

Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - Armenian Reporter

Mar 14, 2025

Mar 13, 2025

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL

Mar 13, 2025

Mar 12, 2025

Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK

Mar 12, 2025

Mar 11, 2025

Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan

Mar 11, 2025

Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq

Mar 11, 2025

Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire

Mar 11, 2025

Mar 10, 2025

Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks

Mar 10, 2025

Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com

Mar 10, 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - Lelezard

Mar 10, 2025

Capricor's DMD Treatment Receives FDA Priority Review Status - StockTitan

Mar 10, 2025

Mar 08, 2025

Rhumbline Advisers Has $636,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Mar 08, 2025

Mar 07, 2025

Capricor Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Capricor Therapeutics to Provide Corporate Update and Participate in Investor Meetings at Leerink’s Global Healthcare Conference 2025 - Nasdaq

Mar 07, 2025

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire

Mar 07, 2025

Can Capricor's DMD Treatment Breakthrough Change Rare Disease Treatment? Key Updates Coming - StockTitan

Mar 07, 2025

New York State Common Retirement Fund Raises Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Mar 07, 2025

Mar 06, 2025